Malika Ammam received her MS degree from the University of Pierre et Marie CURIE in July 2002 and her PhD from the University of Paris Sud XI, France in September 2005. From 2006 to 2007, she worked as a research fellow at the University of Kansas in collaboration with Pinnacle Technology Inc. (USA). From 2007 to 2010, she was a research associate at KU Leuven, Belgium. From 2010 to 2012, she worked at the University of Ontario Institute of Technology in collaboration with Alcohol Countermeasure Systems Corporation, Canada. She has also held the prestigious Rosalind Franklin fellowship.
The endothelial cell protein C receptor (EPCR) suppresses tumor growth in malignant pleural mesothelioma (MPM) by rendering cells more susceptible to cell death-activating mechanisms, according to a study published in Scientific ... Read more
Researchers at Hyogo College of Medicine in Japan recently reviewed the therapeutic agents suitable for the treatment of malignant pleural mesothelioma (MPM) and propose that an anti-CD26 monoclonal antibody and ... Read more
A recent study reports a novel approach based on radiation therapy followed by surgery to treat patients with malignant pleural mesothelioma (MPM). The study, entitled “Accelerated hemithoracic radiation followed by extrapleural pneumonectomy ... Read more
A recent study suggests that a lipid named 1,2-Diarachidonoyl-sn-glycero-3-phosphoethanolamine (DAPE) causes both cell injury/premature death and programmed cell death in malignant pleural mesothelioma (MPM) cells. The paper, entitled “Diarachidonoylphosphoethanolamine induces apoptosis ... Read more
A recent multicenter retrospective study conducted in France suggests that response rate to chemotherapy treatment in patients with malignant pleural mesothelioma (MPM) is low when compared to results from clinical trials. The ... Read more